Baidu
map

JAMA Neurol:突触核蛋白病患者生存率及死亡原因研究

2017-05-17 zhangfan MedSci原创

与普通人群相比,多系统萎缩帕金森患者、路易体痴呆和帕金森病痴呆患者死亡率增加,相比于同龄人共核蛋白病导致的患者寿命缩短并不显著

目前,突触核蛋白病患者与普通人群相比生存和死亡原因的综合研究尚不充分。近日研究人员根据患者年龄和性别就突触核蛋白病生存率和死亡原因开展研究。

研究人员分析了1991年至2010年间罗切斯特流行病学项目记载的帕金森病患者资料。运动障碍专家审查每一个患者的医疗记录,确认并鉴别帕金森病的类型。研究的主要目的是确定年龄和性别调整的各型共核蛋白病死亡风险,确诊至死亡中位时间以及死亡原因。

共461名蛋白病患者,其中279 (60.5%)为男性;452名对照参与者,272 (60.2%)为男性。从1991年至2010年,461名蛋白病患者中,309名(67%)为帕金森病,81人(17.6%)为路易体痴呆, 55人(11.9%)为帕金森病痴呆,16人(3.5%)多系统萎缩性帕金森症。随访发现,316名(68.6%)蛋白病患者以及220名对照者死亡。蛋白病患者较对照组平均提前2年死亡。多系统萎缩帕金森症患者死亡风险最高(风险比,10.51;95% CI,2.92-37.82),之后是路易体痴呆患者(风险比,3.94;95% CI,2.61-5.94),帕金森病痴呆和帕金森病死亡风险相对较低(帕金森病痴呆风险比,3.86;95% CI,2.36-6.30;帕金森病风险比,1.75;95% CI,1.39-2.21)。神经退行性疾病是蛋白病患者最常见的死亡因素,而对照患者中心血管疾病是最常见的死亡因素。

与普通人群相比,多系统萎缩帕金森患者、路易体痴呆和帕金森病痴呆患者死亡率增加,相比于同龄人共核蛋白病导致的患者寿命缩短并不显著。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1999946, encodeId=ed6a19999469e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 26 16:53:00 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986082, encodeId=b69719860820d, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Mar 06 18:53:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903516, encodeId=a45819035169b, content=<a href='/topic/show?id=c8aa6335ed5' target=_blank style='color:#2F92EE;'>#死亡原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63357, encryptionId=c8aa6335ed5, topicName=死亡原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Thu Feb 15 23:53:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932571, encodeId=2e2819325e168, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Dec 13 16:53:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256564, encodeId=ef0a125656412, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri May 19 05:53:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478777, encodeId=0c0214e8777c4, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Fri May 19 05:53:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-06-26 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=1999946, encodeId=ed6a19999469e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 26 16:53:00 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986082, encodeId=b69719860820d, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Mar 06 18:53:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903516, encodeId=a45819035169b, content=<a href='/topic/show?id=c8aa6335ed5' target=_blank style='color:#2F92EE;'>#死亡原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63357, encryptionId=c8aa6335ed5, topicName=死亡原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Thu Feb 15 23:53:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932571, encodeId=2e2819325e168, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Dec 13 16:53:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256564, encodeId=ef0a125656412, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri May 19 05:53:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478777, encodeId=0c0214e8777c4, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Fri May 19 05:53:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1999946, encodeId=ed6a19999469e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 26 16:53:00 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986082, encodeId=b69719860820d, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Mar 06 18:53:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903516, encodeId=a45819035169b, content=<a href='/topic/show?id=c8aa6335ed5' target=_blank style='color:#2F92EE;'>#死亡原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63357, encryptionId=c8aa6335ed5, topicName=死亡原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Thu Feb 15 23:53:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932571, encodeId=2e2819325e168, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Dec 13 16:53:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256564, encodeId=ef0a125656412, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri May 19 05:53:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478777, encodeId=0c0214e8777c4, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Fri May 19 05:53:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1999946, encodeId=ed6a19999469e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 26 16:53:00 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986082, encodeId=b69719860820d, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Mar 06 18:53:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903516, encodeId=a45819035169b, content=<a href='/topic/show?id=c8aa6335ed5' target=_blank style='color:#2F92EE;'>#死亡原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63357, encryptionId=c8aa6335ed5, topicName=死亡原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Thu Feb 15 23:53:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932571, encodeId=2e2819325e168, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Dec 13 16:53:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256564, encodeId=ef0a125656412, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri May 19 05:53:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478777, encodeId=0c0214e8777c4, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Fri May 19 05:53:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1999946, encodeId=ed6a19999469e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 26 16:53:00 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986082, encodeId=b69719860820d, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Mar 06 18:53:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903516, encodeId=a45819035169b, content=<a href='/topic/show?id=c8aa6335ed5' target=_blank style='color:#2F92EE;'>#死亡原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63357, encryptionId=c8aa6335ed5, topicName=死亡原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Thu Feb 15 23:53:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932571, encodeId=2e2819325e168, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Dec 13 16:53:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256564, encodeId=ef0a125656412, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri May 19 05:53:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478777, encodeId=0c0214e8777c4, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Fri May 19 05:53:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1999946, encodeId=ed6a19999469e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 26 16:53:00 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986082, encodeId=b69719860820d, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Tue Mar 06 18:53:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903516, encodeId=a45819035169b, content=<a href='/topic/show?id=c8aa6335ed5' target=_blank style='color:#2F92EE;'>#死亡原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63357, encryptionId=c8aa6335ed5, topicName=死亡原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Thu Feb 15 23:53:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932571, encodeId=2e2819325e168, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Dec 13 16:53:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256564, encodeId=ef0a125656412, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri May 19 05:53:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478777, encodeId=0c0214e8777c4, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Fri May 19 05:53:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]

相关资讯

JAMA Neurol:帕金森综合征中突触核蛋白病明显多于tau蛋白病

以帕金森综合征起病的人群中突触核蛋白病和tau蛋白病的发病频率及分布情况的资料知之甚少,而这对卫生保健规划制定和临床研究有重要影响。来自梅奥临床研究中心的Rodolfo Savica等医师研究了不同帕金森综合征及相关蛋白病的发病率及不同类型的分布情况,发表在2013年7月的JAMA Neurology杂志上,结果显示帕金森综合征相关的蛋白病发病率随年龄急剧增加,男性发病率高于女性。突触核蛋白病临床

Baidu
map
Baidu
map
Baidu
map